Study S000878

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02054897
Acronym: SUSTAIN™1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 388
Start: 2014-02-03
Primary completion: 2015-05-08
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2013-000632-94; OTHER:U1111-1139-3090; REGISTRY:JapicCTI-142442

Registered primary outcomes

Change in HbA1c (Glycosylated Haemoglobin) [Week 0, week 30]

Linked records (13)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015927	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. DeSouza C, The Journal of clinical endocrinology and metabolism	2020	Randomized trial	PMID 31769496 DOI	cites ClinicalTrials.gov:NCT02054897; registry reference DERIVED:31769496
R0018529	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Husain M, Cardiovascular diabetology	2020	Randomized trial	PMID 32998732 DOI	cites ClinicalTrials.gov:NCT02054897; registry reference DERIVED:32998732
R0018857	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Husain M, Diabetes, obesity & metabolism	2020	Other	PMID 31903692 DOI	cites ClinicalTrials.gov:NCT02054897; registry reference DERIVED:31903692
R0009176	Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Overgaard RV, Diabetes, obesity & metabolism	2019	Other trial	PMID 30047216 DOI	registry reference BACKGROUND:30047216
R0009827	GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. Rodbard HW, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2019	Other trial	PMID 30865526 DOI	registry reference BACKGROUND:30865526
R0013158	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Aroda VR, Diabetes & metabolism	2019	Other trial	PMID 30615985 DOI	registry reference RESULT:30615985
R0017746	Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Fonseca VA, The Journal of clinical endocrinology and metabolism	2019	Other	PMID 30938762 DOI	registry reference BACKGROUND:30938762
R0013229	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Carlsson Petri KC, Diabetes therapy : research, treatment and education of diabetes and related disorders	2018	Other trial	PMID 29907893 DOI	cites ClinicalTrials.gov:NCT02054897; registry reference RESULT:29907893
R0018825	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Ahrén B, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 29766634 DOI	registry reference RESULT:29766634
R0020727	Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Petri KCC, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 29748996 DOI	registry reference RESULT:29748996
R0022511	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. Warren M, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 29687620 DOI	registry reference RESULT:29687620
R0023345	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. DeVries JH, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 29862621 DOI	registry reference RESULT:29862621
R0022440	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Sorli C, The lancet. Diabetes & endocrinology	2017	Randomized trial	PMID 28110911 DOI	cites ClinicalTrials.gov:NCT02054897; registry reference RESULT:28110911